Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Mesopic Vision Clear all

Completed Phase 3 Interventional

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

NCT06349759

View directory record Official record

Conditions: Mesopic Vision, Night Vision Loss
Interventions: phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo; Drug
Lead sponsor: Ocuphire Pharma, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 25
States / cities: Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more

Source: ClinicalTrials.gov public record

Updated Mar 11, 2026 · Synced May 22, 2026, 1:32 AM EDT

Completed No phase listed Observational Accepts healthy volunteers

Flicker Fusion Thresholds Between Young and Old Subjects at Various Luminance Levels

NCT03079570

View directory record Official record

Conditions: Age Factor, Age-related Macular Degeneration
Interventions: Not listed
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Andover, Massachusetts

Source: ClinicalTrials.gov public record

Updated Mar 13, 2017 · Synced May 22, 2026, 1:32 AM EDT

Recruiting Phase 3 Interventional

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

NCT07140783

View directory record Official record

Conditions: Vision Loss Night, Vision Disorders
Interventions: 0.75% Phentolamine Ophthalmic Solution, Placebo; Drug
Lead sponsor: Ocuphire Pharma, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 23
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 18 more

Source: ClinicalTrials.gov public record

Updated Sep 30, 2025 · Synced May 22, 2026, 1:32 AM EDT